PLANO, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced participation in the 2025 Bank of America Securities Health Care Conference, to be held May 13-15, 2025, in Las Vegas. Members of the Integer executive leadership team will participate in a fireside chat on Wednesday, May 14, at 10:00 a.m. PT.
A live webcast of the presentation will be accessible under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net.
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: |
| Kristen Stewart | Kelly Butler |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| 551.337.3973 | 469.731.6617 |
| Last Trade: | US$121.77 |
| Daily Change: | 1.30 1.08 |
| Daily Volume: | 382,629 |
| Market Cap: | US$4.250B |
July 10, 2025 April 24, 2025 April 24, 2025 March 18, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
